CagriSema Dual Pathway Metabolic Signaling Compound CagriSema combines two investigational molecules Cagrilintide (amylin analogue) and Semaglutide (GLP 1 receptor agonist), designed to influence key metabolic and appetite regulating pathways. Current Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 eBioMedicine Cagrilintide: The Next Gen Peptide for Weight Loss and Satiety Hubmed When should I consider adding cagrilintide? Cagrilintide is the newest of the weight loss peptides. It works on amylin, which is found in the pancreas. Now, this can be a stand alone product but the Cagrilintide Lumin Peptides A new drug combo of semaglutide (GLP 1 receptor agonist) with cagrilintide (amylin analogue) failed to do as well as tirzepatide (GLP 1 GIP receptor agonist). The future of these medicines is hitting different receptors.